Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof
Innovaderm’s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences’ VTAMA® (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.
Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.
“This is a great milestone for patients – one that we have been working towards for years,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof’s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.”
VTAMA® cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
“VTAMA® cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,” says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. “We appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum – from mild to severe.”
Dr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103629
For information on Innovaderm’s early to late phase study capabilities, visit our website.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information and Patient Information.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Dermavant Sciences
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005175/en/
Contact information
For more information:
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
Anna Tallman
Vice-President, Medical Affairs
Dermavant Sciences
anna.tallman@dermavant.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Antera Brand Back at the Summit of Light Alloy-wheel Producers24.4.2024 14:23:00 CEST | Press release
The Antera brand makes its comeback on the world stage during the 2024 Milan Design Week with a new collection of light alloy wheels. A premium made-in-Italy brand, Antera combines timeless design, cutting-edge technology, and the determination to overcome any obstacle. Its ambassador is the football champion Roberto Baggio, who, thanks to his successful career and winning mindset, is the perfect embodiment of the Italian’s brand spirit of 'No Compromise'. The new Antera advertising campaign’s slogan, "Where instinct meets genius, the myth becomes legend", attests to the dedication, courage, and vision of a brand which is able to project itself into the future. Antera was founded in Milan in 1991 and has produced some of the most iconic models in the field, including the Type 109, a three-spoke wheel that was named as “Alloy Wheel Design of the Year 1994”. G.M.P. Group, a company specialized in the global design and production of alloy wheels, is responsible for bringing it back to its
Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech24.4.2024 14:15:00 CEST | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products. By combining powerful automation with the Parse Evercode platform, customers will have unprecedented access to high-throughput single cell sequencing, enabling them to rapidly generate insights for large-scale studies. Parse’s Evercode single cell technology has enabled researchers to scale their projects to millions of cells or nuclei and has been widely adopted across oncology, immunology, neuroscience, basic research, and drug and target discovery. To facilitate scaling up these projects and to help researchers generate insights more quickly, Parse has developed automation-friendly workflows for high-throughput sample fixation, single cell barcoding, and library preparation. As key providers in the new Labor
AMGTA Releases Research on Sustainability of Powder and Wire Additive Feedstock24.4.2024 13:59:00 CEST | Press release
The Additive Manufacturer Green Trade Association (“AMGTA”) a global advocacy group focused on promoting sustainable additive manufacturing (“AM”) industry practices, announced today the preliminary results of a research project titled “Specific Energy of Metal AM Feedstock: A Comparison.” The study, commissioned by the AMGTA and conducted by Syntec Associates, a research consultancy, in partnership with Divergent Technologies, a complete modular digital factory for complex structures, evaluated three key metal AM feedstock processing approaches—gas atomization, mechanical milling (specifically ball milling), and wire drawing—to determine specific energy requirements for producing feedstock materials. The research findings highlighted that, from an energy perspective, helium gas atomization is the most sustainable method used for gas atomization for metallic powder production of commonly used alloys, followed by argon and then nitrogen. Specific energy consumption for atomization also
KnowBe4 to Acquire Egress24.4.2024 13:00:00 CEST | Press release
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced it has entered into a definitive agreement to acquire Egress, a leader in adaptive and integrated cloud email security. Egress’ Intelligent Email Security suite provides a set of scaled, AI-enabled security tools with adaptive learning capabilities to help prevent, protect and defend organizations against sophisticated email cybersecurity threats. Further terms of the transaction were not disclosed. Organizations globally struggle to contain behavioral-based data breaches, with 74 percent of incidents involving the human element according to Verizon’s Data Breach Investigations Report. By acquiring Egress, KnowBe4 plans to deliver a single platform that aggregates threat intelligence dynamically, offering AI-based email security and training that is automatically tailored relative to risk. “The future of security is personalized AI-driven controls and real-time coac
Vantage Data Centers Expands EMEA Portfolio with First Dublin Campus Featuring Next-Generation Energy Solution24.4.2024 12:00:00 CEST | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into the Irish market with the development of a multi-phase data center campus (DUB1). The company will invest more than €1 billion over multiple phases to support the construction and delivery of the campus in one of the largest data center markets in Europe. The first two phases consist of 52MW of IT capacity, with the first phase expected to be operational in late 2024. Upon completion, DUB1 will mark Vantage’s 14th EMEA campus in a growing regional portfolio that spans seven countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424930079/en/ Vantage Data Centers’ flagship Dublin campus will include 52MW of IT capacity to enable next-generation applications and digital transformation. (Graphic: Business Wire) The company’s flagship Ireland campus will be located approximately nine miles (15 kilometers) f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom